Skip to main content
OpenTrials
Completed

NCT Number: NCT00658983

Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers

Compare Autologous Platelet Enriched Gel versus Metalloproteinase Inhibitor in the healing of chronic lower leg ulcers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Lower Leg Ulcer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Ghent

Ghent, 9000, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 year or older
  • A non-healing chronic lower leg ulcer
  • Platelet ranges of 150000 per ml circulating blood

Exclusion criteria

  • Presence of a tumor or metastatic disease
  • Hypersensitive to collagen regenerated cellulose
  • Hemodynamic unstable patient
  • Hypercoagulability
  • Heart decompensation or angina pectoris

Treatment and study plan

Autologous Platelet Enriched Gel

Other

Treatment with Autologous Platelet Enriched Gel

Metalloproteinase Inhibitor

Other

Treatment with Metalloproteinase Inhibitor (Promogran)

Primary outcomes

  1. Wound healing

    Time frame: 6 weeks

Secondary outcomes

  1. Wound healing

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Collaborators

  • Johnson & Johnson
  • Medtronic

Registry information

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Apr 16, 2008
Registry last updated
Jan 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.